National Cancer Institute National Cancer Institute
U.S. National Institutes of Health National Cancer Institute
Send to Printer
NCI Drug Dictionary

razoxane
An orally bioavailable bis-dioxopiperazine and a derivative of the chelating agent ethylenediaminetetraacetic acid (EDTA) with antineoplastic, antiangiogenic, and antimetastatic activities. Razoxane specifically inhibits the enzyme topoisomerase II without inducing DNA strand breaks, which may result in the inhibition of DNA synthesis and cell division in the premitotic and early mitotic phases of the cell cycle. This agent may also exhibit antiangiogenic and antimetastatic activities although the precise molecular mechanisms of these actions are unknown. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

Foreign brand name:Razoxin
Code names:ICI 59118
ICRF-159

Previous:Rapamune, ras peptide cancer vaccine, rasburicase, ravuconazole, RayGel
Next:Re-186 hydroxyethylidene diphosphonate, Rebetol, Rebif, rebimastat, Recentin